In-depth Analysis of the Immune Responses in the Upper Respiratory Tract of Influenza-infected Children
NCT ID: NCT06998264
Last Updated: 2025-05-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
40 participants
OBSERVATIONAL
2025-03-04
2026-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary objective of this observational study is to quantify the inflammatory response in the nasal cavity and to correlate it with viral load and with clinical parameters. The study also aims to compare the inflammatory response measured in the nose to that measured in the blood.
Participants will have two study visits including a blood draw, several nasal samplings (nasal lining fluid and nasal cells) and a saliva sampling, one within 72 hours of their hospital admission and another one month later. Nasal lining fluid and saliva will be obtained every two or three days until symptoms disappear. During those visits, questions regarding symptoms will be asked.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Epidemiology and Clinical Presentation of H1N1 Infection in Children in Geneva
NCT01022931
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children
NCT01776554
Natural History of Systemic and Nasal Mucosal Immunity After Influenza Vaccination in a Pediatric Population
NCT04963166
Evaluation of Moderate to Severe Influenza Outcomes in Children
NCT02979626
Vaccine Responses to Influenza A H1N1/09 Immunization in High-risk Patients
NCT01022905
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Flu kids
Patients aged 2-5 years old hospitalized with flu-like symptoms and a laboratory-confirmed influenza infection
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Presenting clinical signs of an influenza-like illness
* Having a concomitant positive laboratory test for influenza.
Exclusion Criteria
* Intubation or under invasive mechanical ventilation
* Co-infection with RSV or SARS-CoV-2
2 Years
5 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Geneva
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Arnaud Didierlaurent
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Arnaud Didierlaurent, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Geneva
Arnaud L'Huillier, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Geneva
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Geneva University Hospitals
Geneva, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-01409
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.